Protagenic Therapeutics, Inc. (PTIX) Fair Value 2026

PTIX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 4 models active

Value Trap Risk

WARN (56/100)

Quick Summary — As of 2026-08-27, Protagenic Therapeutics, Inc. (PTIX) trades at $0.91, versus a $3.62 median fair value across its 4 active models — 297.4% above the current price. QOC: 4.6/10. Value Trap Risk: 56/100 (WARN). 4/13 models active. Within that set, the Bayesian DCF component alone returns $3.91.

Key Facts

Ticker
PTIX
Price
$0.91
Quality Score
4.6/10
Value Trap Risk
56/100
Models Active
4/13
Last Updated
Strength: CUCE Ensemble suggests +365.9% upside with 6% confidence
Risk: Value Trap score of 56 suggests caution despite apparent undervaluation

Is Protagenic Therapeutics, Inc. (PTIX) Undervalued or Overvalued in 2026?

According to CirclFi’s 4-model valuation engine, Protagenic Therapeutics, Inc. (PTIX) appears undervalued as of : the median of 4 independent fair value estimates is $3.62, 297.4% above the current price of $0.91. Estimates range from $1.66 to $4.24. PTIX scores 4.6/10 on fundamental quality and 56/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. PTIX’s +297.4% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Protagenic Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give PTIX?

4 Intrinsic Value Models vs. Current Price ($0.91)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $3.91 +329.3%
Ensemble · Low Conviction
 $4.24 +365.9%
Unlock the Full Matrix

Access 2 additional models including ML-RIV, Regime Cross-Sectional.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 4 Models →

Cancel anytime · No contracts · Instant access

What Is PTIX's Fair Value Range?

Spread across 4 independent models · $1.66 to $4.24

CirclFi's 4 active models place Protagenic Therapeutics, Inc. (PTIX) between $1.66 and $4.24 per share, a spread of 71% of the median. The median of that range — $3.62 — is the fair value CirclFi publishes for PTIX, against a current price of $0.91.

Low · ML-RIVHigh · CUCE
$1.66median $3.62$4.24
Where the range comes from
Most bearish modelML Residual Income$1.66
Most bullish modelCUCE$4.24
Model agreement4 bullish · 0 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on PTIX, not a CirclFi price target. How each model works →

What Is Protagenic Therapeutics, Inc. (PTIX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Protagenic Therapeutics, Inc.'s intrinsic value is estimated at a median fair value of $3.62. At a current market price of $0.91, 4 of 4 active valuation models identify upside potential, projecting a median implied return of +297.4%. Notably, CUCE sees the most upside at +365.9% (fair value: $4.24), while ML-RIV is the most conservative at +82.4% ($1.66). The spread between these extremes — +283.4% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About PTIX?

4 of 13 models are currently active for PTIX. All 4 active models suggest the stock trades below fair value. Taken together, their median fair value for PTIX is $3.62 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $3.91 on its own, implying +329.3% upside from the current price. See which stocks rank higher →

How Does PTIX Rank in Biotechnology?

Among 620 Biotechnology stocks, PTIX ranks #431 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Protagenic Therapeutics, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating PTIX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is PTIX a Value Trap?

CirclFi's Value Trap algorithm assigns PTIX a score of 56/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

4 of 13 models are active for Protagenic Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Protagenic Therapeutics, Inc.'s fundamental quality profile registers 4.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +283.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PTIX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PTIX's 4 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Protagenic Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

SIONSionna Therapeutics, Inc.QOC 4.6BCTXBriaCell Therapeutics Corp.QOC 4.6VERAVera Therapeutics, Inc.QOC 4.6NRSNNeuroSense Therapeutics Ltd.QOC 4.6LTRNLantern Pharma Inc.QOC 4.6ATXIAvenue Therapeutics, Inc.QOC 4.6CLLSCellectis S.A.QOC 3.2XFORX4 Pharmaceuticals, Inc.QOC 6.3XBITXBiotech Inc.QOC 5.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: SION · BCTX · VERA · NRSN · LTRN · ATXI · CLLS · XFOR · XBIT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PTIX?

7 companies across all industries closest to PTIX’s Quality of Company score of 4.6/10.

WETOWetour Robotics LimitedQOC 4.6AQMSAqua Metals, Inc.QOC 4.6RBOTVicarious Surgical Inc.QOC 4.6OFSOFS Capital CorporationQOC 4.6BLNCBalance Labs, Inc.QOC 4.6SNYRSynergy CHC Corp.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: WETO · AQMS · RBOT · OFS · BLNC · SNYR · NVDA

Where Does PTIX Sit in CirclFi's Biotechnology Rankings?

PTIX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Protagenic Therapeutics, Inc.’s Valuation?

What is Protagenic Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Protagenic Therapeutics, Inc. (PTIX)'s intrinsic value at $3.62 — the median of 4 independent model estimates as of 2026-08-27, ranging from $1.66 to $4.24. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $3.91 on its own. The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PTIX overvalued or undervalued right now?

At $0.91, 4 of 4 active models suggest PTIX may be undervalued, while 0 indicate potential overvaluation. The median of all 4 fair value estimates is $3.62, 297.4% above the current price of $0.91 — a consensus view that PTIX is undervalued. The assessment depends on which methodology best fits Protagenic Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.6 mean for PTIX?

Protagenic Therapeutics, Inc.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PTIX?

CirclFi analyzes PTIX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 4 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PTIX?

Of the 4 models currently active on PTIX, CUCE is the most bullish at $4.24 per share, and ML Residual Income is the most bearish at $1.66. CirclFi's published fair value for PTIX is the median of that range, $3.62, not either extreme. The gap between the two ends equals 71% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is PTIX a value trap in 2026?

Protagenic Therapeutics, Inc.'s Value Trap score is 56/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 4-model valuation engine, Protagenic Therapeutics, Inc. (PTIX) has a median fair value of $3.62 — 297.4% above the current price of $0.91 — as of 2026-08-27.” Source: circlfi.com/stock/PTIX/ · Methodology
Primary sources for this PTIX valuation
  • Financial statements: Protagenic Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001022899) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PTIX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 4 mathematical frameworks give you clarity on PTIX.

Unlock All 4 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

2 models hidden for PTIX Unlock All 4 — $39/mo